Neuca

Neuca CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Neuca (NEU.WA) as of Oct 22, 2026 is 25.15 %. In the previous year, CapEx to Operating Cash Flow Ratio was 146.94 % — a change of -82.88% (lower).

CapEx/OCF

25.15 %

YoY

-82.88%

Last updated:

CapEx to Operating Cash Flow Ratio of Neuca is 2025 25.15 % . CapEx to Operating Cash Flow Ratio of Neuca was 2024 146.94 % . It decreases by -82.88% lower compared to the previous year.

The Neuca CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
90.29 PLN
Jan 1, 2019
59.98 PLN
Jan 1, 2020
26.23 PLN
Jan 1, 2021
17.57 PLN
Jan 1, 2022
24.25 PLN
Jan 1, 2023
32.67 PLN
Jan 1, 2024
146.94 PLN
Jan 1, 2025
25.15 PLN
The Neuca CapEx/OCF history
YEARCapEx/OCFYoY
25.15 %-82.88%
146.94 %+349.75%
32.67 %+34.76%
24.25 %+37.97%
17.57 %-33.00%
26.23 %-56.27%
59.98 %-33.58%
90.29 %+87.52%
48.15 %+87.48%
25.68 %+47.45%
17.42 %-4.61%
18.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

CapEx to Operating Cash Flow Ratio of Neuca is 25.15 % in 2025.

CapEx to Operating Cash Flow Ratio of Neuca changed from 146.94 % to 25.15 %, representing a -82.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Neuca since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Neuca with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Neuca

All Key Metrics — Neuca